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Abstract
Objective
The Death-Associated Protein Kinase 1 (DAPK1) gene has been frequently investigated in
cervical cancer (CC). The aim of the present study was to carry out a systematic review and
a meta-analysis in order to evaluate DAPK1 promoter methylation as an epigenetic marker
for CC risk.
Methods
A systematic literature search was carried out. The Cochrane software package Review
Manager 5.2 was used. The fixed-effects or random-effects models, according to heteroge-
neity across studies, were used to calculate odds ratios (ORs) and 95% Confidence Inter-
vals (CIs). Furthermore, subgroup analyses were conducted by histological type, assays
used to evaluate DAPK1 promoter methylation, and control sample source.
Results
A total of 20 papers, published between 2001 and 2014, on 1929 samples, were included in
the meta-analysis. DAPK1 promoter methylation was associated with an increased CC risk
based on the random effects model (OR: 21.20; 95%CI = 11.14–40.35). Omitting the most
heterogeneous study, the between study heterogeneity decreased and the association
increased (OR: 24.13; 95% CI = 15.83–36.78). The association was also confirmed in all
the subgroups analyses.
Conclusions
A significant strong association between DAPK1 promoter methylation and CC was
shown and confirmed independently by histological tumor type, method used to evaluate
methylation and source of control samples. Methylation markers may have value in early
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detection of CC precursor lesions, provide added reassurances of safety for women who
are candidates for less frequent screens, and predict outcomes of women infected with
human papilloma virus.
Introduction
Cervical cancer (CC) is the second most common cancer in women worldwide [1, 2]. The
identification and treatment of women with cervical intraepithelial neoplasia (CIN) or carci-
noma in situ (CIS), the precursor lesions of invasive CC, represent an important component
of the prevention of CC [3]. CC arises by distinct morphologic changes from normal epithe-
lium and progresses to carcinoma through a series of well-defined pre-invasive lesions. His-
tologically, CC presents as either squamous cell carcinoma (SCC) or adenocarcinoma (AC)
[4], with SCC predominating. Persistence of human papilloma virus (HPV) is the main etio-
logic factor in the development of CC and the precursor lesions [5, 6]. However, only a small
fraction of HPV-infected CIN lesions progress to invasive cancer, thus, other host factors
play a role in cervical carcinogenesis [2, 7].
Among the putative molecular alterations involved in the neoplastic process, aberrant
methylation might be a crucial event in the oncogenesis [8]. A recent meta-analysis confirmed
that global DNA methylation levels, in tissues of several cancers, were significantly lower in
cancer patients than in healthy controls [9]. Approximately 60% of all human promoters are
associated with CpG islands. In the genome of untransformed cells, ~90% of all promoters
are unmethylated [10]. Conversely, in cancer, the methylation of CpG regions of gene pro-
moter is associated with inappropriate transcriptional repression and gene inactivation. Sig-
nificantly, many of the inactivated genes are tumor suppressor genes [11,12] and the
inhibition of these genes by methylation is implicated in cancer initiation, development, and
progression [13]. Although it is difficult to establish whether such epigenetic alterations are
causative or consequential of cancer, there is evidence that they can occur early in the neo-
plastic process [14]. Recently, the role of epigenetic mechanisms of gene inactivation has been
examined in cervical oncogenesis [13,15–19].
Among the involved genes, the Death-Associated Protein Kinase 1 (DAPK1) gene has been
frequently investigated in CC. DAPK1 is a novel 160 kd calmodulin-dependent serine/threonine
kinase operating as a positive mediator of apoptosis, while apoptosis links to the development,
progression, and metastasis of human cancer [20]. The DAPK1 C-terminal serine-rich tail pep-
tide, which is conserved in death-domain-containing proteins, plays a negative regulatory role
in the inhibition of DAPK1, whereas the removal of this region enhances the killing activity
[21]. Hypermethylation of DAPK1 has been frequently reported in various cancers types,
including colon [22], head and neck [23], urinary bladder [24], lung [25–27], B cell lymphoma
[28] and ovary [29]. In addition, it has been associated with the advanced stages of tumor devel-
opment [30] and a poor prognosis in non-small cell lung carcinoma [31]. Since DAPK1 is a pos-
itive mediator of apoptosis, the silencing ofDAPK1 disabled the DAPK-mediated apoptosis and
might then prompt metastasis in the cancer cells [32]. Furthermore, cells lacking DAPK1
expression via promoter methylation became more invasive and metastatic [33].
In addition to the functional implications of gene inactivation in tumor development, genes
that are frequently aberrantly methylated in specific tumours have been used as molecular tar-
gets for the detection of neoplastic cells in body fluids providing additional targets for non-
invasive early diagnosis and for cancer monitoring [34–36]. Thus, developing a panel of
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methylation markers may have value in early detection of CC precursor lesions, provide added
reassurances of safety for women who are candidates for less frequent screens, and predict out-
comes of women infected with HPV [34].
The aim of the present study was to carry out a systematic review and a meta-analysis in
order to summarize the current published studies and to evaluate DAPK1 promoter methyla-
tion as an epigenetic marker for CC risk.
Methods
Search strategy and selection criteria
Firstly, a systematic literature search in the Medline database, using PubMed, was carried out
for epidemiological studies, published before July 2014, investigating the association between
gene promoter methylation and CC risk. Literature search was conducted independently by
two Authors using the keywords “promoter methylation” and “cervical neoplasia”. The
searches were limited to studies written in English; abstracts and unpublished studies were not
included. Moreover, the reference lists from selected articles were checked to search for further
relevant studies. The aim of the first selection was to identify studies that investigated the asso-
ciation between promoter methylation of any gene and CC risk; no studies were excluded a pri-
ori for weakness of design or data quality. Accordingly, articles were selected only if they
satisfied the following criteria: i) case-control or cohort study designs, and ii) studies that
assessed the association of gene promoter methylation and CC. Subsequently, since DAPK1
gene has been identified as the most common analyzed and studied gene, a meta-analysis of
articles reporting the association between DAPK1 promoter methylation and CC risk was per-
formed. Thus for inclusion in the quantitative analysis, studies had to meet the following crite-
ria: i) studies that assessed the association between DAPK1methylation and CC and ii)
provided data about the frequency ofDAPK1methylation in cancer and in control groups. Fur-
thermore, exclusion criteria were as follows: i) studies that did not use exfoliated cells, cervical
biopsies or urines as samples and ii) in which control or cancer groups included individuals
with various types of precancerous lesions. The preferred reporting items for systematic
reviews and meta-analysis (PRISMA) guidelines were followed [37] (S1 and S2 Files).
Data extraction and quality assessment
Two of the Authors independently reviewed all the eligible studies and abstracted the following
information in a standard format: first Author’s last name, year of publication, country where
the study was performed, sample type, experimental methods to assess DAPK1methylation
and number of cases and controls subjects.
Statistical Analysis
All data were analyzed using the Review Manager 5.2 software provided by the Cochrane Col-
laboration (http://ims.cochrane.org/revman).
Forest plots were generated to illustrate the study-specific effect sizes along with a 95% CI.
The fixed-effects or random-effects models, according to heterogeneity across studies, were
used to calculate the ORs and 95% CIs in order to assess the association between DAPK1 pro-
moter methylation and CC risk. Where a value of zero in the number of promoter methylation
events caused problems with computation of the ORs for individual studies, the Review Man-
ager 5.2 software provided to add a value of 0.5 to all cells of the related crosstab [38].
Heterogeneity across studies, was measured using the Q-test based on the χ2 statistic, con-
sidering significant statistical heterogeneity as p<0.1. As Cochran’s test only indicates the
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presence of heterogeneity and not its magnitude, we also reported the I2 statistic, which esti-
mates the percentage of outcome variability that can be attributed to heterogeneity across stud-
ies. An I2 value of 0% denotes no observed heterogeneity, whereas, 25% is ‘‘low”, 50% is
‘‘moderate” and 75% is ‘‘high” heterogeneity [39]. We also estimated the between-study vari-
ance using tau-squared (t) statistic [40].
Furthermore, subgroup analyses were conducted by histological type (SCC and AC), by
assays used to evaluate DAPK1 promoter methylation (Methylation Specific PCR—MSP and
real-time quantitative MSP—qMSP), and by control sample source (normal cervical tissues—
NT and benign cervical tissues—BCT). A sensitivity analysis was performed to find relatively
poor-quality studies by the omission of a single study at a time and to see whether a particular
omission could affect the overall OR value and the heterogeneity across studies.
To determine the presence of publication bias, the symmetry of the funnel plots in which
ORs were plotted against their corresponding standard errors were assessed.
Results
Search results and data characteristics
The detailed steps of the systematic review and meta-analysis process are given as a PRISMA
flow chart (Fig 1). A total of 519 articles were retrieved from the database. After exclusion of
studies that not met the inclusion criteria, DAPK1 resulted the most common analyzed gene.
Fig 1. Flow diagram of study selection.
doi:10.1371/journal.pone.0135078.g001
DAPK1 Promoter Methylation and Cervical Cancer Risk
PLOS ONE | DOI:10.1371/journal.pone.0135078 August 12, 2015 4 / 15
Table 1. Studies included in the systematic review and in the meta-analysis.
Reference Author Year Country Method Source of
cancer
sample
Source of
control
Methylation
Tumor
Methylation
Control
Note
43 Banzai et al. 2014 Japan MSP Biopsy NT 40/53 1/24
41 Dong et al. 2001 Korea MSP Biopsy BCT 27/53 0/24
61 Feng et al. 2007 Senegal qMSP Urine NT 31/63 1/16
60 Feng et al.* 2005 Senegal MSP Biopsy 50/91 3/140 Control group
included ASCUS
51 Flatley et al. 2009 UK MSP Scrape NT 17/42 0/40
59 Gustafson
et al.*
2004 USA MSP Scrape NA NA Case group
included LSIL and
HSIL
52 Henken et al.* 2007 Netherlands MS-MLPA Biopsy NA NA No control group
50 Huang et al. 2011 Taiwan MSP Scrape NT 13/26 3/15
16 Iliopoulos et al. 2009 Greece qMSP Biopsy NT 41/61 0/15
13 Jeong et al. 2006 Korea MSP Biopsy BCT 35/78 1/24
58 Kahn et al.* 2008 USA qMSP Scrape NA NA No control group
56 Kalantari et al.
*
2014 USA Sequencing Biopsy NA NA Inadequate data
46 Kang et al. 2005 Korea MSP Biopsy BCT 60/82 0/17
48 Kang et al.* 2006 Korea MSP Biopsy NA NA No control group
49 Kim et al. 2010 Korea MSP Scrape BCT 50/69 11/41
44 Leung et al. 2008 China MSP Biopsy AT 60/107 0/27
62 Missaoui et al. 2011 Tunisia MSP Biopsy BCT 10/14 0/8
55 Narayan et al. 2003 USA MSP Biopsy NT 37/82 0/8
47 Niyazi et al. 2012 China MSP Biopsy BCT 19/30 1/30
3 Reesink-
Peters et al.
2004 Netherlands qMSP Scrape NT 35/48 2/41
57 Shivapurkar
et al.
2007 USA qMSP Biopsy BCT 24/45 0/12
36 Sun et al. 2012 China MSP Scrape NT 11/14 157/336
53 Wisman et al. 2006 Netherlands qMSP Scrape BCT 13/28 0/19
45 Yang et al. 2004 China MSP Biopsy AT 51/85 0/100
55 Yang et al. 2010 Netherlands qMSP Biopsy BCT 31/60 5/20
42 Yang et al.* 2006 China MSP Biopsy NA NA No control group
17 Zhao et al. 2008 China MSP Biopsy BCT 34/52 0/20
Total 639/1092 182/837 Studies included in
meta-analysis
* studies excluded from meta-analysis
MSP: Methylation Speciﬁc PCR;
qMSP: quantitative real-time MSP;
NT: Normal cervical Tissue;
BCT: Benign Cervical Tissue;
AT: normal cervical tissues adjacent to the tumor;
ASCUS: Atypical Squamous Cells of Undetermined Signiﬁcance;
LSIL: Low-grade Squamous Intraepithelial Lesion;
HSIL: High-grade Squamous Intraepithelial Lesion.
doi:10.1371/journal.pone.0135078.t001
DAPK1 Promoter Methylation and Cervical Cancer Risk
PLOS ONE | DOI:10.1371/journal.pone.0135078 August 12, 2015 5 / 15
Subsequently, one article was added through manual searching with reference list and thus
27 papers, published between 2001 and 2014, were included in the systematic review and
summarized in Table 1. A total of 13 studies were from Asian countries (48%) [13, 17, 36,
41–50], 6 from European countries (22%) [3, 16, 51–54], 5 from USA (19%) [55–59] and 3
from Africa (11%) [60–62]. All studies evaluated DAPK1 promoter methylation in SCC and
12 studies (44.4%) also in AC. Regarding the method of promoter methylation evaluation,
the “gold standard method”, used in most studies (67%), was MSP, followed by qMSP (26%),
sequencing (3.5%) and Methylation specific-multiplex ligation-dependent probe amplifica-
tion (MS-MLPA) (3.5%).
Meta-analysis
Of the 27 selected articles, 4 studies conducted without a control group, 2 studies which
included precancerous lesions in control or in case groups and 1 study which reported inade-
quate data, were excluded from the meta-analysis. Thus, 20 studies (74%) evaluating DAPK1
promoter methylation both in tumor and in healthy control samples were included in the pres-
ent meta-analysis. Overall, the studies reported results obtained from 1929 samples: 1092 from
cancer patients and 837 from controls. Regarding the source of control samples, 10 studies
evaluated DAPK1 promoter methylation in BCT from patients having gynaecological diseases
such as uterine myoma, adenomyoma, and uterine prolapse, 8 studies in NT from healthy peo-
ple and 2 studies in normal cervical tissues adjacent to the tumor.
DAPK1 promoter methylation was associated with an increased CC risk with a pooled OR of
19.97 (95% CI = 13.57–29.38) based on the fixed effects model. However, due to the significant
heterogeneity (I2 = 49%; p = 0.007), a pooled OR of 21.20 (95%CI = 11.14–40.35), based on the
random effects model, was obtained (Fig 2). Subgroup analyses were performed by histological
types, methods for methylation analysis and sources of control samples. The association
between DAPK1 promoter methylation and CC was confirmed in each subgroup (S1 Table).
In addition, the sensitivity analysis found the study by Yang et al. (2010) [54], as the rela-
tively poor-quality study. When this study [54] was omitted, the between study heterogeneity
decreased to I2 = 39% (p = 0.04), and the association between DAPK1 promoter methylation
and CC risk increased (OR: 24.13; 95% CI = 15.83–36.78) (S1 Fig)
Subgroup analyses omitting the heterogeneous study [54] were performed. Subgroup analy-
sis by histological types showed that the heterogeneity totally disappeared in AC subgroup (I2
= 0%; p = 0.93) and the association was confirmed both in SCC (OR = 33.84; 95% CI = 15.61–
73.37; based on the random effects model) (Fig 3A) and AC (OR = 21.89; 95% CI = 8.64–55.48;
based on the fixed effects model) (Fig 3B) subgroups. Furthermore, subgroup analysis based on
assays methods used to evaluate DAPK1 promoter methylation was performed including the
two common techniques, MSP and qMSP. The ORs were 23.45 (95% CI = 10.56–52.09), based
on the random effects model, in MSP subgroup, and 34.25 (95% CI = 12.34–95.04), based on
the fixed effects model, in qMSP subgroup, while the I2 were 51% and 0%, respectively (Fig 4A
and 4B). The subgroup analysis by source of control sample, and particularly between NT and
BCT, reported that the ORs were 16.99 for NT (95% CI = 9.09–31.76) and 22.00 for BCT (95%
CI = 11.95–40.51), respectively. Heterogeneity in NT and BCT subgroups were low with I2 =
48% and I2 = 14%, respectively (Fig 5).
The funnel plot of the pooled analysis (Fig 6), which is quite symmetric, suggests no signifi-
cant bias among the included studies, however the shapes of the subgroups analyses (S2, S3
and S4 Figs) indicate small to moderate asymmetry, therefore publication bias cannot be
completely excluded as a factor of influence on the present meta-analysis.
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Discussion
Tumor suppressor genes belonging to different pathways, as cell adhesion, DNA repair, cell
cycle checkpoint control and nuclear receptors, have been found to be hypermethylated in CIN
and CC [41, 55, 60].
A previous review [63] summarized the results of 51 published studies on methylation anal-
ysis performed in cervical tissues and cells and proposed that the combination of DAPK1,
CADM1, and RARB genes would appear the most promising methylated gene panel to obtain
an appropriate performance for CC screening.
The recent meta-analysis by Xiong et al. [64], including 15 studies, suggested a strong asso-
ciation between DAPK1 promoter methylation and CC (pooled OR = 19.66; 95%CI = 8.72–
44.31) indicating that DAPK1 promoter methylation may be a biomarker during cervical
carcinogenesis.
Our study reports results of a more comprehensive meta-analysis and, taking into account
that promoter methylation could be a tissue-specific event [65, 66], provides a subgroup analy-
sis by histological tumor type. The present meta-analysis concerned 20 unique articles and, on
a total of 1092 from cancer patients and 837 control samples, reports a significant pooled OR
of 21.20. Because of the moderate heterogeneity between studies, a sensitivity analysis and sub-
group analyses by histological tumor types, sources of control samples and assays used to
Fig 2. Forest plot of DAPK1 promoter methylation and cervical cancer risk using random effects model.
doi:10.1371/journal.pone.0135078.g002
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evaluate DAPK1 promoter methylation were performed. Interestingly, removing the most het-
erogeneous study [54], the association between DAPK1 promoter methylation and CC risk
increased (OR: 24.13) and was confirmed in SCC and AC subgroups with a heterogeneity
between study of I2 = 48% and I2 = 0%, respectively.
The gold standard method of promoter methylation evaluation was MSP, in which PCR
products are run on a gel, and the results are reported as methylated or unmethylated at the
target DNA sequence. Consequently, this method does not allow the identification of partial
Fig 3. Subgroups analysis based on histological cancer type, omitting one heterogeneous study. (A) Squamous Cell Carcinoma (SCC) subgroup
analysis, based on the random effects model. (B) Adenocarcinoma (AC) subgroup analysis, based on the fixed effects model.
doi:10.1371/journal.pone.0135078.g003
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levels of methylation, a feature which is extremely relevant both biologically and clinically.
Thus, qMSP has been developed in recent years to overcome this limitation of conventional
MSP. In fact, qMSP is reported to be more specific and more sensitive than conventional MSP
and allows for high-throughput analysis, making it more suitable as a screening tool [67–69].
In the present meta-analysis, considering these two detection methods, both subgroups
reported a significant association between DAPK1 promoter methylation and CC. Although
heterogeneity between studies stood moderately high in MSP subgroup (I2 = 51%), the hetero-
geneity in qMSP subgroup decreased to I2 = 0%.
Fig 4. Subgroup analysis based on assaysmethods used, omitting one heterogeneous study. (A) Methylation-Specific PCR (MSP) subgroup
analysis, based on the random effects model. (B) Quantitative real-time MSP (qMSP) subgroup analysis, based on the fixed effects model.
doi:10.1371/journal.pone.0135078.g004
DAPK1 Promoter Methylation and Cervical Cancer Risk
PLOS ONE | DOI:10.1371/journal.pone.0135078 August 12, 2015 9 / 15
Finally, the subgroup analysis by source of control sample revealed a significant association
in both subgroups; the heterogeneity in NT and BCT subgroups was moderately low (I2 = 48%
and I2 = 14%, respectively).
The present study has some limitations. The number of studies included in the meta-analysis
is modest (n = 20). Moreover, since all studies included had a case-control design, it is not possi-
ble to clarify ifDAPK1 promoter methylation is an early cancer-causing aberration or an effect
of carcinogenesis. Accordingly, the potential of DNAmethylation measurements requires vali-
dation in retrospective studies, but ultimately in large prospective clinical studies [70].
In addition, although sensitivity analysis and subgroup analyses were performed, the pooled
estimates should be interpreted with caution, due to the moderate heterogeneity across studies.
Finally, the small to moderate asymmetry in the funnel plots, suggests that publication bias
cannot be completely excluded.
The usefulness of DAPK1 tumour suppressor gene hypermethylation as an epigenetic
marker is under intense investigation in many different cancers, including CC and its precursor
lesions and the present meta-analysis provides scientific evidences to this debate, showing a
significant strong association between DAPK1 promoter methylation and CC. This result was
confirmed independently by histological tumor type, method used to evaluate methylation and
source of control samples.
Fig 5. Subgroups analysis based on source of control sample, omitting one heterogeneous study [54]. NT: Normal cervical Tissue; BCT: Benign
Cervical Tissue.
doi:10.1371/journal.pone.0135078.g005
DAPK1 Promoter Methylation and Cervical Cancer Risk
PLOS ONE | DOI:10.1371/journal.pone.0135078 August 12, 2015 10 / 15
Supporting Information
S1 Fig. Sensitivity analysis of 20 studies with the fixed effects model.
(TIF)
S2 Fig. Funnel plot of subgroups analysis based on histological cancer type, omitting one
heterogeneous study [54]. SCC: Squamous Cell Carcinoma; AC: Adenocarcinoma.
(TIF)
S3 Fig. Funnel plot of subgroups analysis based on method, omitting one heterogeneous
study [54].MSP: Methylation-Specific PCR; qMSP: quantitative real-time MSP.
(TIF)
S4 Fig. Funnel plot of subgroups analysis based on source of control sample, omitting one
heterogeneous study [54]. NT: Normal cervical Tissue; BCT: Benign cervical Tissue.
(TIF)
S1 File. PRISMA checklist.
(PDF)
S2 File. Meta-analysis on Genetic Association Studies Checklist.
(PDF)
S1 Table. Subgroups analyses based on histological cancer type, method and source of con-
trol sample. SCC: Squamous Cell Carcinoma; AC: Adenocarcinoma; MSP: Methylation-
Fig 6. Funnel plot ofDAPK1methylation and cervical cancer risk.
doi:10.1371/journal.pone.0135078.g006
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Specific PCR; qMSP: quantitative real-time MSP; M+: the number of subjects/samples with
methylation; M-: the number of subjects/samples with no methylation; NT: Normal cervical
Tissue; BCT: Benign cervical Tissue.
(TIF)
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